Navigation Links
New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
Date:6/11/2009

<24 months; and 3) a single dose of Prevenar 13 at age 24 to <72 months. Each of the 3 regimens was shown to elicit immune response levels against all 13 serotypes that were either comparable to or greater than the IgG antibody concentrations achieved in infants after a 3-dose infant series and to have acceptable tolerability and safety profiles.

Overall, the most frequently reported adverse events in the Phase 3 trials included injection site reactions, (redness, swelling, and tenderness), fever (greater than or equal to 38 degrees C/100.4 degrees F), irritability, drowsiness, restless sleep, decreased appetite, vomiting, diarrhea and rash.

Health Economic Models

Three health economic models presented at ESPID estimated the potential public health and economic impact of Prevenar 13. The results of the analyses in the Netherlands, the UK, and Germany and the US suggested that the introduction of Prevenar 13, if approved, to national immunization programs has the potential to further reduce PD levels in children who are vaccinated as well as in the unvaccinated population (through a herd effect). Based on these economic models, the researchers estimated that routine vaccination with Prevenar 13 could be cost effective or cost saving.

Registration Status

To date, Wyeth has submitted regulatory applications for the pediatric use of Prevenar 13 in more than 45 countries. In December 2008, Wyeth submitted a marketing authorization application (MAA) for Prevenar 13 to the European Medicines Agency (EMEA). In March 2009, Wyeth submitted a Biologic License Application (BLA) for Prevenar 13 to the U.S. Food and Drug Administration (FDA). Last month, the FDA granted the BLA priority review -- a designation given to products that, if approved, would be a significant therapeutic or public health advance. Prevenar 13 is also being studied in
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 19, 2014 According to market ... Points; WLAN Controllers; Wireless gateways)]- Global Advancements, Forecasts ... the global Outdoor Wi-Fi market with analysis and ... MarketsandMarkets also identifies the drivers and the restrains ... trends, opportunities and challenges. , Browse 65 market ...
(Date:10/18/2014)... The Asian arthroscopic devices report defines and segments ... of revenue. The arthroscopic devices market in Asia is ... a CAGR of 6.5% from 2013 to 2018. , ... market, to get an idea of the in-depth analysis ... of arthroscopic devices market in the same region, and ...
(Date:10/18/2014)... York, NY (PRWEB) October 18, 2014 ... a healthy rate in the five years to 2014. ... several federal renewable energy tax credits that encouraged the ... have enacted renewable portfolio standards (RPSs), which require local ... percentage of their total energy portfolio. Increased campaigning for ...
(Date:10/17/2014)... Air Force Office of Scientific Research grant to examine ... that will provide clues for predicting fatigue in aircraft ... said the new technology and process would be better ... wing., "We,ll be able to determine metal fatigue at ... this scale," Huang said. "Certain patterns of surface roughness ...
Breaking Biology Technology:Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 2Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 4The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 2Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 3UT Arlington project to detect possible damages in aircraft parts early in process 2
... Reports 2nd Quarter and Six Months Profit Resulting From Enhanced ... ... InstaCare Corp., (OTC,Bulltein Board: ISCR), a leading distributor of at-home ... developer of,patent-pending technologies for e-health and EMR applications, reported,financial results ...
... Neb., Aug. 20 LI-COR announces its second,webinar in ... In Vivo Imaging: Near Infrared Optical Imaging of Mice, ... Near-infrared (NIR) fluorescence offers dramatic benefits for in ... of penetration and,decreased autofluorescence and light scatter that occur ...
... Mass., Aug. 20 GSI Group Inc.,(Nasdaq: GSIG ... of the tender offer by its indirect wholly-owned subsidiary ... stock of,Excel Technology, Inc. (Nasdaq: XLTC ). The ... York City time, on Tuesday, August 19,2008., The ...
Cached Biology Technology:InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008 2InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008 3InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008 4InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008 5InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008 6LI-COR August 27th On-Line Webinar Introduces New Approach to Small Animal In Vivo Imaging 2GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period 2GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period 3
(Date:10/15/2014)... resistance to bacterial pneumonia in female mice to an ... Females are naturally more resistant to respiratory infections than ... that increased resistance to bacterial pneumonia in female mice ... (NOS3). They also show that this enzyme is ultimately ... estrogen. , The team, lead by Professor Lester Kobzik ...
(Date:10/15/2014)... 15, 2014   Neurotechnology , a provider ... availability of the VeriLook Surveillance 3.0 software ... real-time biometric face identification using live video streams ... The new version not only identifies faces in ... objects while they are moving through the video ...
(Date:10/14/2014)... years since T. rex took its last ... is breathing life back into dinosaurs using high-powered computer ... has important implications for how dinosaurs used their noses ... of smell and cool their brains. , "Dinosaurs ... Jason Bourke, lead author of the new study published ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... the leading cause of death in the United States ... for individuals with specific forms of muscular dystrophy. Recent ... could help a variety of organs in the body, ... heart could benefit from these treatments. According to a ...
... at the Hebrew University of Jerusalem has discovered a way ... detector developed by Prof. Joseph Almog of the Hebrew University,s ... nitrate. When sprayed on cotton swabs taken from the hands ... urea nitrate, the chemical will turn a blood red hue. ...
... over a controversial hypothesis of biodiversity and species abundance is ... 1 November 2007 issue of the journal Nature. The ... of the world,s most vulnerable ecosystems -- tropical forests and ... the so-called "neutral theory of biodiversity." "We,re helping to ...
Cached Biology News:Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart 2HU scientist finds way to catch terrorists red-handed 2Why do so many species live in tropical forests and coral reefs? 2Why do so many species live in tropical forests and coral reefs? 3Why do so many species live in tropical forests and coral reefs? 4
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Rabbit polyclonal antibody to GluR2...
...
... materials for 1,464 array sample elements. , , ,Includes: ... , Blocker BSA in PBS (10X): 50 ml ... Phosphate Buffered Saline: 8 packs , 10% Tween-20: ... Luminol Enhancer: 2 x 25 ml , SuperSignal West ...
Biology Products: